Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | KCNMA1 | Q12791 | 4/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046406 | 1.00 | POLB (0.69) | POLBALOX15MAPK1GAAALDH1A1 | |
| SCHEMBL7717051 | 1.00 | POLB (0.69) | POLBALOX15MAPK1GAAALDH1A1 | |
| SCHEMBL31661769 | 1.00 | POLB (0.69) | POLBALOX15MAPK1GAAALDH1A1 | |
| SCHEMBL7718043 | 1.00 | POLB (0.69) | POLBALOX15MAPK1GAAALDH1A1 | |
| SCHEMBL7719057 | 0.95 | POLB (0.71) | POLBALOX15MAPK1GAAALDH1A1 | |
| SCHEMBL13593325 | 0.90 | POLB (0.55) | POLBALOX15MAPK1GAAALDH1A1 | |
| SCHEMBL13593333 | 0.90 | POLB (0.55) | POLBALOX15MAPK1GAAALDH1A1 | |
| SCHEMBL13166882 | 0.89 | POLB (0.76) | POLBALOX15MAPK1GAATDP1 | |
| SCHEMBL31661644 | 0.88 | POLB (0.56) | POLBALOX15MAPK1GAAALDH1A1 | |
| SCHEMBL5655283 | 0.88 | POLB (0.56) | POLBALOX15MAPK1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| CN-106456662-A | Compositions of pentosan polysulfate for oral administration and methods of use thereof | 奥利金制药公司 | 2017-02-22 | — | — | CN | claimed |
| EP-0979225-A4 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2001-08-01 | — | — | EP | claimed |
| EP-0979225-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2000-02-16 | — | — | EP | claimed |
| WO-1998049135-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-11-05 | — | — | WO | claimed |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | LE ROUX DANIELLE MARIE (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| CN-106456662-A | Compositions of pentosan polysulfate for oral administration and methods of use thereof | 奥利金制药公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-1015008-A4 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2006-08-09 | — | — | EP | disclosed |
| US-7071214-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-0979225-A4 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2001-08-01 | — | — | EP | disclosed |
| EP-1015008-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0979225-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2000-02-16 | — | — | EP | disclosed |
| US-5863944-A | CARRIER IS SELECTED FROM N-2(AMINO-5-FLUOROBENZOYL)8-AMINO CARPRYLIC ACID, 4-(N-(5-FLUORO-2-AMINOBENZOYL)4-AMINOPHENYL) BUTYRIC ACID, 8-(2-HYDROXY-5-CHLOROANILINOCARBONYL) OCTANOIC ACID AND SALTS | EMISPHERE TECHNOLOGIES, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| WO-1998049135-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998034632-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | VIP, GIPR, SLC10A2 | POLB 1323/4885ALOX15 1799/4885MAPK1 2609/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | POLB 2682/4885ALOX15 423/4885MAPK1 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.